Survivin-targeting artificial microRNAs mediated by adenovirus suppress tumor activity in cancer cells and xenograft models

Molecular Therapy Nucleic Acids

Volumn 3, Issue 11, 2014, Pages e208-

  Chi, Yudan ^a   Wang, Xiang ^a   Yang, Yong ^a   Zhang, Chao ^a   Ertl, Hildegund C J ^b   Zhou, Dongming ^a  

^a INSTITUTE PASTEUR OF SHANGHAI   (China)

^b WISTAR INSTITUTE   (United States)

Author keywords

Artificial microRNA; Cancer treatment; Survivin

Indexed keywords

ADENOVIRUS VECTOR; ARTIFICIAL MICRORNA; CASPASE 3; MICRORNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN P53; SURVIVIN; UNCLASSIFIED DRUG;

ADENOVIRIDAE; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GENE THERAPY; CELL CYCLE ARREST; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENE REPLICATION; GENE REPRESSION; GENE SILENCING; GENE TARGETING; GENE TRANSFER; HELA CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MEDIATOR; MITOSIS; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR XENOGRAFT; UTERINE CERVIX CARCINOMA; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT;

EID: 84928032027     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2014.59     Document Type: Article

References (60)

1. Hanahan, D and Weinberg, RA (2011). Hallmarks of cancer: the next generation. Cell 144: 646-674.
2. Li, F and Altieri, DC (1999). The cancer antiapoptosis mouse survivin gene: characterization of locus and transcriptional requirements of basal and cell cycle-dependent expression. Cancer Res 59: 3143-3151.
3. Han, J, Soletti, RC, Sadarangani, A, Sridevi, P, Ramirez, ME, Eckmann, L et al. (2013). Nuclear expression of β-catenin promotes RB stability and resistance to TNF-induced apoptosis in colon cancer cells. Mol Cancer Res 11: 207-218.
4. Kawasaki, H, Altieri, DC, Lu, CD, Toyoda, M, Tenjo, T and Tanigawa, N (1998). Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 58: 5071-5074.
5. Tamm, I, Wang, Y, Sausville, E, Scudiero, DA, Vigna, N, Oltersdorf, T et al. (1998). IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 58: 5315-5320.
6. Lu, CD, Altieri, DC and Tanigawa, N (1998). Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res 58: 1808-1812.
7. Saitoh, Y, Yaginuma, Y and Ishikawa, M (1999). Analysis of Bcl-2, Bax and Survivin genes in uterine cancer. Int J Oncol 15: 137-141.
8. Tanaka, K, Iwamoto, S, Gon, G, Nohara, T, Iwamoto, M and Tanigawa, N (2000). Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 6: 127-134.
9. Kamihira, S, Yamada, Y, Hirakata, Y, Tomonaga, M, Sugahara, K, Hayashi, T et al. (2001). Aberrant expression of caspase cascade regulatory genes in adult T-cell leukaemia: survivin is an important determinant for prognosis. Br J Haematol 114: 63-69.
10. Shin, S, Sung, BJ, Cho, YS, Kim, HJ, Ha, NC, Hwang, JI et al. (2001). An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 40: 1117-1123.
11. Wang, J, Xu, Z and Zhang, M (2007). Downregulation of survivin expression and elevation of caspase-3 activity involved in pitavastatin-induced HepG 2 cell apoptosis. Oncol Rep 18: 383-387.
12. Chandele, A, Prasad, V, Jagtap, JC, Shukla, R and Shastry, PR (2004). Upregulation of survivin in G2/M cells and inhibition of caspase 9 activity enhances resistance in staurosporine-induced apoptosis. Neoplasia 6: 29-40.
13. Beardmore, VA, Ahonen, LJ, Gorbsky, GJ and Kallio, MJ (2004). Survivin dynamics increases at centromeres during G2/M phase transition and is regulated by microtubule-attachment and Aurora B kinase activity. J Cell Sci 117(Pt 18): 4033-4042.
14. Kim, JY, Chung, JY, Lee, SG, Kim, YJ, Park, JE, Yoo, KS et al. (2006). Nuclear interaction of Smac/DIABLO with Survivin at G2/M arrest prompts docetaxel-induced apoptosis in DU145 prostate cancer cells. Biochem Biophys Res Commun 350: 949-954.
15. He, L and Hannon, GJ (2004). MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 5: 522-531.
16. Aucher, A, Rudnicka, D and Davis, DM (2013). MicroRNAs transfer from human macrophages to hepato-carcinoma cells and inhibit proliferation. J Immunol 191: 6250-6260.
17. Lu, T, Shao, N and Ji, C (2013). Targeting microRNAs to modulate TRAIL-induced apoptosis of cancer cells. Cancer Gene Ther 20: 33-37.
18. Hu, T, Fu, Q, Chen, P, Ma, L, Sin, O and Guo, D (2009). Construction of an artificial MicroRNA expression vector for simultaneous inhibition of multiple genes in mammalian cells. Int J Mol Sci 10: 2158-2168.
19. Baek, MN, Jung, KH, Halder, D, Choi, MR, Lee, BH, Lee, BC et al. (2010). Artificial microRNA-based neurokinin-1 receptor gene silencing reduces alcohol consumption in mice. Neurosci Lett 475: 124-128.
20. Fan, ZD, Zhang, L, Shi, Z, Gan, XB, Gao, XY and Zhu, GQ (2012). Artificial microRNA interference targeting AT(1a) receptors in paraventricular nucleus attenuates hypertension in rats. Gene Ther 19: 810-817.
21. Wang, S, Shu, JZ, Cai, Y, Bao, Z and Liang, QM (2012). Establishment and characterization of MTDH knockdown by artificial MicroRNA interference - functions as a potential tumor suppressor in breast cancer. Asian Pac J Cancer Prev 13: 2813-2818.
22. Guo, HM, Zhang, XQ, Xu, CH and Zou, XP (2011). Inhibition of invasion and metastasis of gastric cancer cells through snail targeting artificial microRNA interference. Asian Pac J Cancer Prev 12: 3433-3438.
23. Wang, Z, He, YL, Cai, SR, Zhan, WH, Li, ZR, Zhu, BH et al. (2008). Expression and prognostic impact of PRL-3 in lymph node metastasis of gastric cancer: its molecular mechanism was investigated using artificial microRNA interference. Int J Cancer 123: 1439-1447.
24. Liang, Z, Wu, H, Reddy, S, Zhu, A, Wang, S, Blevins, D et al. (2007). Blockade of invasion and metastasis of breast cancer cells via targeting CXCR4 with an artificial microRNA. Biochem Biophys Res Commun 363: 542-546.
25. Reichert, S, Reinboldt, V, Hehlgans, S, Efferth, T, Rödel, C and Rödel, F (2012). A radiosensitizing effect of artesunate in glioblastoma cells is associated with a diminished expression of the inhibitor of apoptosis protein survivin. Radiother Oncol 103: 394-401.
26. Blum, R, Jacob-Hirsch, J, Rechavi, G and Kloog, Y (2006). Suppression of survivin expression in glioblastoma cells by the Ras inhibitor farnesylthiosalicylic acid promotes caspase-dependent apoptosis. Mol Cancer Ther 5: 2337-2347.
27. Petersen, J and Hagan, IM (2003). S. pombe aurora kinase/survivin is required for chromosome condensation and the spindle checkpoint attachment response. Curr Biol 13: 590-597.
28. Mesri, M, Wall, NR, Li, J, Kim, RW and Altieri, DC (2001). Cancer gene therapy using a survivin mutant adenovirus. J Clin Invest 108: 981-990.
29. Pennati, M, Folini, M and Zaffaroni, N (2008). Targeting survivin in cancer therapy. Expert Opin Ther Targets 12: 463-476.
30. Tanaka, T, Kitamura, H, Inoue, R, Nishida, S, Takahashi-Takaya, A, Kawami, S et al. (2013). Potential survival benefit of anti-apoptosis protein: survivin-derived peptide vaccine with and without interferon alpha therapy for patients with advanced or recurrent urothelial cancer-results from phase I clinical trials. Clin Dev Immunol 2013: 262967.
31. Carrasco, RA, Stamm, NB, Marcusson, E, Sandusky, G, Iversen, P and Patel, BK (2011). Antisense inhibition of survivin expression as a cancer therapeutic. Mol Cancer Ther 10: 221-232.
32. Chu, X, Chen, L, Wang, J, Guan, X, Geng, H, Zhang, Q et al. (2010). SiRNA-mediated survivin inhibition enhances chemo- or radiosensivity of colorectal cancer cells in tumor-bearing nude mice. Hepatogastroenterology 57: 1445-1452.
33. Li, Z, Yin, PH, Yang, SS, Li, QY, Chang, T, Fang, L et al. (2013). Recombinant attenuated Salmonella typhimurium carrying a plasmid co-expressing ENDO-VEGI151 and survivin siRNA inhibits the growth of breast cancer in vivo. Mol Med Rep 7: 1215-1222.
34. Xu, GC, Zhang, P, Leng, F, Pan, L, Li, ZY, Yu, DD et al. (2012). Inhibition of lymphatic metastases by a survivin dominant-negative mutant. Oncol Res 20: 579-587.
35. Casati, C, Dalerba, P, Rivoltini, L, Gallino, G, Deho, P, Rini, F et al. (2003). The apoptosis inhibitor protein survivin induces tumor-specific CD8+ and CD4+ T cells in colorectal cancer patients. Cancer Res 63: 4507-4515.
36. Honma, I, Kitamura, H, Torigoe, T, Takahashi, A, Tanaka, T, Sato, E et al. (2009). Phase I clinical study of anti-apoptosis protein survivin-derived peptide vaccination for patients with advanced or recurrent urothelial cancer. Cancer Immunol Immunother 58: 1801-1807.
37. Xiong, H, Yu, S, Hu, G and Zhuang, L (2006). Effects of Survivin expression suppressed by short hairpin RNA on MCF-7 cells. J Huazhong Univ Sci Technolog Med Sci 26: 305-307.
38. Wu, JB, Nan, QZ, Ma, GF, Gong, W, Chen, L, Lin, YZ et al. (2007). [Short hairpin RNA-mediated survivin gene silencing inhibits invasion and metastasis of human colon carcinoma cell line SW480 in vitro]. Nan Fang Yi Ke Da Xue Xue Bao 27: 951-954.
39. De Guire, V, Caron, M, Scott, N, Ménard, C, Gaumont-Leclerc, MF, Chartrand, P et al. (2010). Designing small multiple-target artificial RNAs. Nucleic Acids Res 38: e140.
40. Ruan, Q, Wang, P, Wang, T, Qi, J, Wei, M, Wang, S et al. (2014). MicroRNA-21 regulates T-cell apoptosis by directly targeting the tumor suppressor gene Tipe2. Cell Death Dis 5: e1095.
41. Bader, AG, Brown, D and Winkler, M (2010). The promise of microRNA replacement therapy. Cancer Res 70: 7027-7030.
42. Janssen, HL, Reesink, HW, Lawitz, EJ, Zeuzem, S, Rodriguez-Torres, M, Patel, K et al. (2013). Treatment of HCV infection by targeting microRNA. N Engl J Med 368: 1685-1694.
43. Marquez, RT, Bandyopadhyay, S, Wendlandt, EB, Keck, K, Hoffer, BA, Icardi, MS et al. (2010). Correlation between microRNA expression levels and clinical parameters associated with chronic hepatitis C viral infection in humans. Lab Invest 90: 1727-1736.
44. Mak, RH and Cheung, WW (2012). MicroRNAs: a new therapeutic frontier for muscle wasting in chronic kidney disease. Kidney Int 82: 373-374.
45. Nana-Sinkam, SP and Croce, CM (2013). Clinical applications for microRNAs in cancer. Clin Pharmacol Ther 93: 98-104.
46. Hendrie, PC and Russell, DW (2005). Gene targeting with viral vectors. Mol Ther 12: 9-17.
47. Norian, LA, James, BR and Griffith, TS (2011). Advances in Viral Vector-Based TRAIL Gene Therapy for Cancer. Cancers (Basel) 3: 603-620.
48. Bett, AJ, Haddara, W, Prevec, L and Graham, FL (1994). An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci USA 91: 8802-8806.
49. Bett, AJ, Prevec, L and Graham, FL (1993). Packaging capacity and stability of human adenovirus type 5 vectors. J Virol 67: 5911-5921.
50. Zhou, D, Zhou, X, Bian, A, Li, H, Chen, H, Small, JC et al. (2010). An efficient method of directly cloning chimpanzee adenovirus as a vaccine vector. Nat Protoc 5: 1775-1785.
51. Gus-Brautbar, Y, Johnson, D, Zhang, L, Sun, H, Wang, P, Zhang, S et al. (2012). The anti-inflammatory TIPE2 is an inhibitor of the oncogenic Ras. Mol Cell 45: 610-618.
52. Yoo, DR, Jang, YH, Jeon, YK, Kim, JY, Jeon, W, Choi, YJ et al. (2009). Proteomic identification of anti-cancer proteins in luteolin-treated human hepatoma Huh-7 cells. Cancer Lett 282: 48-54.
53. Meyers, MO, Anthony, CT, Coy, DH, Murphy, WA, Drouant, GJ, Fuselier, J et al. (1998). Multiply radioiodinated somatostatin analogs induce receptor-specific cytotoxicity. J Surg Res 76: 154-158.
54. Tu, H, Bonura, C, Giannini, C, Mouly, H, Soussan, P, Kew, M et al. (2001). Biological impact of natural COOH-terminal deletions of hepatitis B virus X protein in hepatocellular carcinoma tissues. Cancer Res 61: 7803-7810.
55. Murray, EM, Grobler, JA, Markel, EJ, Pagnoni, MF, Paonessa, G, Simon, AJ et al. (2003). Persistent replication of hepatitis C virus replicons expressing the beta-lactamase reporter in subpopulations of highly permissive Huh7 cells. J Virol 77: 2928-2935.
56. Nicholson, DW, Ali, A, Thornberry, NA, Vaillancourt, JP, Ding, CK, Gallant, M et al. (1995). Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 376: 37-43.
57. Sakahira, H, Enari, M and Nagata, S (1998). Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis. Nature 391: 96-99.
58. Pigault, C, Follenius-Wund, A, Schmutz, M, Freyssinet, JM and Brisson, A (1994). Formation of two-dimensional arrays of annexin V on phosphatidylserine-containing liposomes. J Mol Biol 236: 199-208.
59. Ealovega, MW, McGinnis, PK, Sumantran, VN, Clarke, MF and Wicha, MS (1996). bcl-xs gene therapy induces apoptosis of human mammary tumors in nude mice. Cancer Res 56: 1965-1969.
60. Zheng, Y, Yin, L, Chen, H, Yang, S, Pan, C, Lu, S et al. (2012). miR-376a suppresses proliferation and induces apoptosis in hepatocellular carcinoma. FEBS Lett 586: 2396-2403.